Figure S4



Characterization of vaccine's DCs properties. BM-DC cells were differentiated ex-vivo, exposed to Gal-3 deficient (Gal-3^{LOW}) or control (Gal-3^{HIGH}) tumor cell lysate, and matured O.N as described in Methods. For each condition, 1.10^6 cells were stained with the corresponding antibodies and analyzed with BD FACSAria III Flow cytometer. **(a)** Total number of CD11c + used in vaccine after BM-DC differentiation for each condition **(b)** To measure phagocytic capacity, BM-DCs were cultured in the presence of 0,5 mg/ml Alexa 647 Dextran (Invitrogen) for 1 hour at 37°C and the MFI of CD11c+ cells was quantified. Baseline fluorescence was obtained culturing BM-DCs + dextran at 4°C for 1 hour and then substracted from each replicate's MFI. **(c)** Percentage of CD11c+ cells presenting MHCII and CD80 expression after O.N in vitro maturation. (Means were compared using Student's t-test, n=4, NS= not significative)